Biotech Blues: Their Stocks Tank as Newly Public Firms Find Trouble
The urge to do an IPO was strong, and for some, much too early. Maybe staying private before maturing is a good idea for companies, especially biotech ones. That’s...
Tag: Biotech Special Report 2022
Asset Allocation
Up and Coming Biotech Innovations Investors Should Know About
Investors name some key companies and strategies they see promise in.